TY - JOUR T1 - Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study JO - Archivos de Bronconeumología T2 - AU - Monforte,Víctor AU - Ussetti,Piedad AU - Castejón,Raquel AU - Sintes,Helena AU - Pérez,Virginia Luz AU - Laporta,Rosalía AU - Sole,Amparo AU - Cifrián,José Manuel AU - Marcos,Pedro J. AU - Redel,Javier AU - Arcos,Ibai Los AU - Berastegui,Cristina AU - Alonso,Rodrigo AU - Rosado,Silvia AU - Escriva,Juan AU - Iturbe,David AU - Ovalle,Juan Pablo AU - Vaquero,José Manuel AU - López-Meseguer,Manuel AU - Mendoza,Alberto AU - Gómez-Ollés,Susana SN - 03002896 M3 - 10.1016/j.arbres.2020.12.024 DO - 10.1016/j.arbres.2020.12.024 UR - https://www.archbronconeumol.org/en-predictive-value-immune-cell-functional-articulo-S030028962100003X AB - IntroductionImmune cell functional assay (ImmuKnow®) is a non-invasive method that measures the state of cellular immunity in immunosuppressed patients. We studied the prognostic value of the assay for predicting non-cytomegalovirus (CMV) infections in lung transplant recipients. MethodsA multicenter prospective observational study of 92 patients followed up from 6 to 12 months after transplantation was performed. Immune cell functional assay was carried out at 6, 8, 10, and 12 months. ResultsTwenty-three patients (25%) developed 29 non-CMV infections between 6 and 12 months post-transplant. At 6 months, the immune response was moderate (ATP 225–525ng/mL) in 14 (15.2%) patients and low (ATP<225ng/mL) in 78 (84.8%); no patients had a strong response (ATP≥525ng/mL). Only 1 of 14 (7.1%) patients with a moderate response developed non-CMV infection in the following 6 months compared with 22 of 78 (28.2%) patients with low response, indicating sensitivity of 95.7%, specificity of 18.8%, positive predictive value (PPV) of 28.2%, and negative predictive value (NPV) of 92.9% (AUC 0.64; p=0.043). Similar acute rejection rates were recorded in patients with mean ATP≥225 vs. <225ng/mL during the study period (7.1% vs. 9.1%, p=0.81). ConclusionAlthough ImmuKnow® does not seem useful to predict non-CMV infection, it could identify patients with a very low risk and help us define a target for an optimal immunosuppression. ER -